Profound Medical Reports 87% Revenue Growth in Q3 2025 Amid Increased Losses

Profound Medical Corp. reported significant financial results for the third quarter and the first nine months of 2025, reflecting a notable increase in revenue and ongoing operational challenges. For the three months ended September 30, 2025, the company generated total revenue of $5.3 million, a substantial increase of 87% compared to $2.8 million in the same period of 2024. This growth was driven by a rise in both recurring non-capital revenue and capital equipment sales. For the nine months ending September 30, 2025, total revenue reached $10.1 million, up 56% from $6.5 million in the prior year. Despite this revenue growth, the company reported a net loss of $34.4 million for the nine-month period, compared to a loss of $22.9 million in 2024.

The financial performance reflects a strategic focus on expanding the commercialization of its TULSA-PRO system, which utilizes MRI-guided technology for prostate tissue ablation. The company has also been investing in research and development, with R&D expenses increasing by 33% to $16.3 million for the nine months ended September 30, 2025, driven by higher headcount and costs associated with clinical trials. Selling, general, and administrative expenses also rose significantly, increasing by 52% to $25.0 million, reflecting the company's efforts to enhance its sales force and marketing initiatives.

Operationally, Profound Medical has seen an increase in customer engagement, with a growing number of procedures performed using its TULSA-PRO system. The company reported a gross profit margin of 73% for the nine months ended September 30, 2025, up from 63% in the previous year, indicating improved operational efficiency. However, the company’s cash position has deteriorated, with cash reserves decreasing to $24.8 million from $54.9 million at the end of 2024. This decline raises concerns about the company's liquidity, as management indicated that current cash balances may not be sufficient to fund operations over the next year.

Looking ahead, Profound Medical is actively seeking additional financing to support its operations and growth initiatives. The company has acknowledged the risk of breaching financial covenants under its credit agreement with CIBC, which could have significant implications for its operations. Management is focused on securing the necessary capital to continue its commercialization efforts and maintain compliance with its financial obligations. The outlook remains uncertain, as the company navigates the challenges of expanding its market presence while managing its financial health.